Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. Nieto Y, et al. Among authors: thall p. Biol Blood Marrow Transplant. 2012 Nov;18(11):1677-86. doi: 10.1016/j.bbmt.2012.05.011. Epub 2012 May 27. Biol Blood Marrow Transplant. 2012. PMID: 22643322 Free PMC article.
Allogeneic blood stem cell transplantation in advanced hematologic cancers.
Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Körbling M. Przepiorka D, et al. Among authors: thall p. Bone Marrow Transplant. 1997 Mar;19(5):455-60. doi: 10.1038/sj.bmt.1700692. Bone Marrow Transplant. 1997. PMID: 9052911
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. van Besien K, et al. Among authors: thall p. Biol Blood Marrow Transplant. 1997 Aug;3(3):150-6. Biol Blood Marrow Transplant. 1997. PMID: 9310192 Clinical Trial.
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Estey EH, et al. Among authors: thall pf. Blood. 1999 Apr 15;93(8):2478-84. Blood. 1999. PMID: 10194425 Free article. Clinical Trial.
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Körbling M, Deisseroth AB, Champlin R. Przepiorka D, et al. Among authors: thall p. Bone Marrow Transplant. 1999 May;23(10):977-81. doi: 10.1038/sj.bmt.1701764. Bone Marrow Transplant. 1999. PMID: 10373061 Clinical Trial.
Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.
Estey EH, Shen Y, Thall PF. Estey EH, et al. Among authors: thall pf. Blood. 2000 Jan 1;95(1):72-7. Blood. 2000. PMID: 10607687 Free article.
The authors used the parametric model of Shen and Thall to estimate, in particular, T(C) (time to CR), T(C,D) (time from CR to death = residual survival after CR), and T(C,R) (residual disease-free survival [DFS] after CR) as functions of the covariates noted above and to …
The authors used the parametric model of Shen and Thall to estimate, in particular, T(C) (time to CR), T(C,D) (time from CR to death …
273 results